|Bid||0.00 x 800|
|Ask||0.00 x 400|
|Day's Range||57.16 - 59.38|
|52 Week Range||41.25 - 66.34|
|Beta (3Y Monthly)||1.44|
|PE Ratio (TTM)||78.22|
|Earnings Date||Oct 23, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||70.89|
Merit Medical (MMSI) is likely to gain traction in the global breast lesion localization market, courtesy of the Cianna Medical acquisition.
GNC Holdings (GNC) discourages with sluggish domestic retail comps. However, it delivers a strong performance in e-commerce business as well as at International segment.
Merit Medical Systems, Inc. (MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced that it has completed the acquisition of Cianna Medical, Inc. headquartered in Aliso Viejo, California, in a merger transaction through which Cianna Medical has become a wholly-owned subsidiary of Merit. Cianna Medical is a leader in wire-free breast localization and has been focused on breast conservation for 11 years. Cianna Medical develops, manufactures and markets innovative medical products designed to reduce costs, improve quality and reduce the anxiety and stress breast cancer treatments place on women and their families. Its research, development and commercialization teams developed the first non-radioactive, wire-free breast localization system and the world’s only technology that utilizes RADAR in human tissue.
Within Animal Health business of Phirbo Animal (PAHC), reduced selling prices across certain countries partially offset its international volume growth.
Haemonetics' (HAE) year-over-year growth in Q2 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
Canopy Growth (CGC) is poised to gain from continued strength in the Canadian medical cannabis market in the fiscal second quarter.
A shift in BioScrip's (BIOS) strategy to focus on growing its core revenue mix plus contract changes with the UnitedHealthcare dent the company's revenue rise in Q3.
We are encouraged by the year-over-year rise in Genomic Health's (GHDX) revenues in Q3, driven by solid performances in the United States and internationally.
CVS Health's (CVS) year-over-year growth in the top line was driven by a strong Pharmacy Services segment, benefiting from the upside in the specialty services.